Search results
Results from the WOW.Com Content Network
Primary age-related tauopathy (PART) is a neuropathological designation introduced in 2014 to describe the neurofibrillary tangles (NFT) that are commonly observed in the brains of normally aged and cognitively impaired individuals that can occur independently of the amyloid plaques of Alzheimer's disease (AD).
Current Alzheimer Research is a peer-reviewed medical journal covering the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer's disease. [ 3 ] Abstracting and indexing
Alzheimer Disease and Associated Disorders is a quarterly peer-reviewed medical journal publishing original research findings and new approaches to diagnosis and treatment for Alzheimer's disease and related disorders. Articles published emphasize research in humans including epidemiologic studies, clinical trials and experimental studies ...
It is an uncommon form of Alzheimer's, accounting for only 5–10% of all Alzheimer's cases. About 60% have a positive family history of Alzheimer's and 13% of them are inherited in an autosomal dominant manner. Most cases of early-onset Alzheimer's share the same traits as the "late-onset" form and are not caused by known genetic mutations.
Posterior cortical atrophy (PCA), also called Benson's syndrome, is a rare form of dementia which is considered a visual variant or an atypical variant of Alzheimer's disease (AD). [1] [2] [3] The disease causes atrophy of the posterior part of the cerebral cortex, resulting in the progressive disruption of complex visual processing. [4]
Alzheimer's disease is a progressive neurodegenerative disorder associated with aging, which occurs both sporadically (the most common form of diagnosis) or due to familial passed mutations in genes associated with Alzheimer's pathology. [1] [2] Common symptoms associated with Alzheimer's disease include: memory loss, confusion, and mood ...
Blarcamesine (developmental code name ANAVEX 2-73) is an experimental drug which is under development for the treatment of Alzheimer's disease and a variety of other indications. [1] Blarcamesine acts as an agonist of the sigma σ 1 receptor, the muscarinic acetylcholine M 1 receptor, and the ionotropic glutamate NMDA receptor. [2] [1]
By supporting research projects around the world, it seeks to increase the chances of finding treatments for Alzheimer's disease, related dementias and cognitive aging. [ 7 ] [ 8 ] [ 9 ] The ADDF has invested nearly $65 million to fund some 450 Alzheimer's drug discovery programs and clinical trials in academic centers and biotechnology ...